secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001730430-26-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M
--------------------------------------------------------------------------------

- ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.
- 2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.
- Cash and short-term investments $468.1 million, no debt; net income $22.6 million in Q1 2026.
- KPL-387 Phase 2 data in recurrent pericarditis expected in 2H 2026; Phase 3 trial by year-end.
- Over 4,550 prescribers for ARCALYST in recurrent pericarditis; average therapy duration approaching 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/0001730430-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/knsa-20260428x8k.htm
  HTML page:      https://secwatch.observer/filing/0001730430-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer